NCT06991790View on ClinicalTrials.gov

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions

TNBC

Interventions

DRUG

Sacituzumab Govitecan (SG)+Toripalimab

"Sacituzumab govitecan (Trodelvy): 10mg/kg, administered by intravenous infusion on day 1 and day 8.~Toripalimab: 240mg, administered by intravenous infusion on day 1."

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Peking University Cancer Hospital & Institute

OTHER